%0 Journal Article
%A Nicolay, Jan
%A Melchers, Susanne
%A Albrecht, Jana D
%A Assaf, Chalid
%A Dippel, Edgar
%A Stadler, Rudolf
%A Wehkamp, Ulrike
%A Wobser, Marion
%A Zhao, Jing
%A Burghaus, Ina
%A Schneider, Sven
%A Gülow, Karsten
%A Goerdt, Sergij
%A Schürch, Christian M
%A Utikal, Jochen
%A Krammer, Peter
%T Dimethyl fumarate treatment in relapsed and refractory cutaneous T cell lymphoma - a multicenter phase II study.
%J Blood
%V 142
%N 9
%@ 0006-4971
%C Washington, DC
%I American Society of Hematology
%M DKFZ-2023-01023
%P 794-805
%D 2023
%Z #EA:A370#LA:D030# / 2023 Aug 31;142(9):794-805
%X Targeted therapies for cutaneous T-cell lymphoma (CTCL) are limited and curative approaches are lacking. Furthermore, relapses and drug induced side effects are major challenges in the therapeutic management of CTCL patients creating an urgent need for new, effective therapies. Pathologic constitutive NF-κB activity leads to apoptosis resistance in CTCL cells and thus represents a promising therapeutic target in CTCL. In a preclinical study we showed the potential of dimethyl fumarate (DMF) to block NF-κB and specifically kill CTCL cells (Nicolay et al.: Blood 2016). To translate these findings into a clinical setting, we performed a multicentric phase II study evaluating oral DMF therapy in 25 patients with CTCL stage Ib-IV over 24 weeks (EudraCT number 2014-000924-11/NCT number NCT02546440). Endpoints were safety and efficacy. We evaluated skin involvement (mSWAT), pruritus, quality of life and blood involvement if applicable as well as translational data. In the skin, 7/23 patients (30.4
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37217183
%R 10.1182/blood.2022018669
%U https://inrepo02.dkfz.de/record/276211